Stimulation of the immune system, reduction of plasma ACE2, increase of the parasympathetic nervous system and fascia flexibility through cryotherapy at minus 90 degrees.
Conditions
Interventions
Group 1: Intervention 18 x Cryotherapie within 9 weeks followed by 9 weeks waiting period after intervention
Sponsors
Stiftung Immunweltmeister e. V.
Eligibility
Sex/Gender
All
Age
45 Years to 75 Years
Inclusion criteria
Inclusion criteria: none
Exclusion criteria
Exclusion criteria: Contraindications for whole-body cryotherapy are the following: pregnancy, severe hypertension (blood pressure > 180/100), acute or recent myocardial infarction, unstable angina, arrhythmia, symptomatic cardiovascular disease, pacemaker, peripheral arterial occlusive disease, venous thrombosis, acute or recent cerebrovascular accident, uncontrolled seizures, Raynaud's syndrome, fever, tumor disease, symptomatic lung disease, Blood clotting disorders, severe anemia, infections, cold allergies and acute kidney and urinary tract diseases, as well as epileptic seizures, further increased intraocular pressure. If you suffer from the above conditions or meet the exclusion criteria, you will unfortunately not be able to participate in our study, as we cannot guarantee that cryotherapy can have positive effects for you. The same applies to patients with glaucoma, for which there is no exclusion of liability, e.g. in case of unexplained increase in intraocular pressure. Exclusion criteria for the study are more than 4 cups of coffee per day, more than 2 alcoholic beverages per day, a strong diet change and extreme sports, as well as other cold applications such as ice bathing.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Surrogate endpoint: Through 18 sessions cryotherapy reduction of free plasma ACE2 concentration Surrogate endpoint: 18 sessions of cryotherapy improve immune target test with IL-2, IL-10, IFN-gamma and TNF-alpha values Surrogate endpoint: 18 sessions of cryotherapy improve HRV values mean HP, SDNN, SD1, SD2 and E-1, E/I, RMSSD Surrogate endpoint: Change in body composition measured by bioimpedance analysis Surrogat endpoint: Improvement of fascial flexibility | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoint: 18 Sessions of cryotherapy improve TICS Stress score | — |
Countries
Germany
Contacts
Public ContactPunito Michael Aisenpreis
Stiftung Immunweltmeister e. V.
Outcome results
None listed